Zentalis PharmaceuticalsL Financials

ZNTL Stock  USD 17.15  0.68  3.81%   
The value of Average Assets is estimated to slide to about 446.2 M. The value of Earnings Before Interest Taxes and Depreciation Amortization EBITDA is expected to slide to about (242.1 M).
With this module, you can analyze Zentalis financials for your investing period. You should be able to track the changes in Zentalis PharmaceuticalsL individual financial statements over time to develop the understanding of its risk, liquidity, profitability, or other critical and vital indicators.

Zentalis Most Recent Estimates

EPS Estimate Next Quarter
Diluted Eps
EPS Estimate Current Year
EPS Estimate Next Year
EPS Estimate Current Quarter
Understanding current and past Zentalis PharmaceuticalsL Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Zentalis PharmaceuticalsL's financial statements are interrelated, with each one affecting the others. For example, an increase in Zentalis PharmaceuticalsL's assets may result in an increase in income on the income statement.
The financial analysis of Zentalis PharmaceuticalsL is a critical element in measuring its lifeblood. The essential information of the day-to-day investment outlook for Zentalis PharmaceuticalsL includes many different criteria found on its balance sheet. For example, investors should never minimize Zentalis PharmaceuticalsL's ability to pay suppliers or employees on time, making sure interest payments are not accumulating or correctly timing where and how to re-invest extra cash. Any individual investor needs to monitor Zentalis PharmaceuticalsL's cash flow, debt, and profitability to effectively and accurately make more informed decisions on whether to invest in Zentalis PharmaceuticalsL.

Cash and Equivalents

53.83 Million

Evaluating Zentalis PharmaceuticalsL's financials involves analyzing a range of financial metrics and ratios to gain insights into the company's financial health and performance. However, considering all of Zentalis PharmaceuticalsL's profitability, liquidity ratios, and efficiency indicators at the same time could be an enormous task, and our Financial Distress score can provide you with a snapshot of the Zentalis PharmaceuticalsL's relative financial performance

Chance Of Distress

Less than 26

Zentalis PharmaceuticalsLlc has less than 26 (%) percent chance of experiencing financial distress in the next two years of operations. The calculation of odds of distress for Zentalis PharmaceuticalsL stock is tightly coupled with the Probability of Bankruptcy. It complements the equity performance score by supplying investors with insight into company financials without requiring them to know too much about all of the complex accounting and financial indicators surrounding the entity.
Please note, Zentalis PharmaceuticalsL's odds of distress score SHOULD NOT be confused with the real chance of Zentalis PharmaceuticalsLlc filing for bankruptcy protection for chapters 7, 11, 12, or 13. We define Financial Distress as an operational condition where an entity such as Zentalis is having difficulty meeting its current financial obligations towards its creditors or delivering on the expectations of its investors. Macroaxis derives these conditions daily from public financial statements and analysis of stock prices reacting to market conditions or economic downturns, including short-term and long-term historical volatility. Other factors considered include Zentalis PharmaceuticalsL's liquidity analysis, revenue patterns, R&D expenses, and commitments, as well as public headlines and social sentiment.
More Info
The data published in Zentalis PharmaceuticalsL's official financial statements usually reflect Zentalis PharmaceuticalsL's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Zentalis PharmaceuticalsL. For example, before you start analyzing numbers published by Zentalis accountants, it's critical to develop an understanding of what Zentalis PharmaceuticalsL's liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of Zentalis PharmaceuticalsL's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Zentalis PharmaceuticalsL's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Zentalis PharmaceuticalsL's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Zentalis PharmaceuticalsLlc. Please utilize our Beneish M Score to check the likelihood of Zentalis PharmaceuticalsL's management to manipulate its earnings.

Zentalis PharmaceuticalsL Company Summary

Zentalis PharmaceuticalsL competes with Codexis, Calyxt, Cumberland Pharmaceuticals, AcelRx Pharmaceuticals, and Avadel Pharmaceuticals. Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. The company was incorporated in 2014 and is based in New York, New York. Zentalis Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 177 people.
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
InstrumentUSA Stock View All
ExchangeNASDAQ Exchange
LocationNew York; U.S.A
Business Address1359 Broadway, New
IndustryHealth Care
BenchmarkNYSE Composite
Phone212 433 3791
CurrencyUSD - US Dollar
You should never invest in Zentalis PharmaceuticalsL without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Zentalis Stock, because this is throwing your money away. Analyzing the key information contained in Zentalis PharmaceuticalsL's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.

Zentalis PharmaceuticalsL Key Financial Ratios

Generally speaking, Zentalis PharmaceuticalsL's financial ratios allow both analysts and investors to convert raw data from Zentalis PharmaceuticalsL's financial statements into concise, actionable information that can be used to evaluate the performance of Zentalis PharmaceuticalsL over time and compare it to other companies across industries. There are many critical financial ratios that investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Zentalis PharmaceuticalsL reports annually and quarterly.

Zentalis Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Zentalis PharmaceuticalsL's current stock value. Our valuation model uses many indicators to compare Zentalis PharmaceuticalsL value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Zentalis PharmaceuticalsL competition to find correlations between indicators driving Zentalis PharmaceuticalsL's intrinsic value. More Info.
Zentalis PharmaceuticalsLlc is rated below average in net income category among related companies. It is rated below average in debt to equity category among related companies . Zentalis PharmaceuticalsL Net Income is quite stable at the moment as compared to the past year. The company's current value of Net Income is estimated at (243.04 Million). Comparative valuation analysis is a catch-all model that can be used if you cannot value Zentalis PharmaceuticalsL by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Zentalis PharmaceuticalsL's Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Zentalis PharmaceuticalsL's earnings, one of the primary drivers of an investment's value.

Zentalis PharmaceuticalsL Systematic Risk

Zentalis PharmaceuticalsL's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Zentalis PharmaceuticalsL volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Beta measures systematic risk based on how returns on Zentalis PharmaceuticalsL correlated with the market. If Beta is less than 0 Zentalis PharmaceuticalsL generally moves in the opposite direction as compared to the market. If Zentalis PharmaceuticalsL Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Zentalis PharmaceuticalsL is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Zentalis PharmaceuticalsL is generally in the same direction as the market. If Beta > 1 Zentalis PharmaceuticalsL moves generally in the same direction as, but more than the movement of the benchmark.

About Zentalis PharmaceuticalsL Financials

What exactly are Zentalis PharmaceuticalsL Financials? Typically, a company's financial statements are the reports that show the financial position of the company. Three primary documents fall into the category of financial statements. These documents include Zentalis PharmaceuticalsL's income statement, its balance sheet, and the statement of cash flows. Potential Zentalis PharmaceuticalsL investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Zentalis PharmaceuticalsL investors may use each financial statement separately, they are all related. The changes in Zentalis PharmaceuticalsL's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Zentalis PharmaceuticalsL's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.

Steps to analyze Zentalis PharmaceuticalsL Financials for Investing

There are several different ways that investors can use financial statements to try and predict whether a stock price will go up or down. Unfortunately, there is no surefire formula, but there are some general guidelines you should consider when looking at the numbers. First, realize what kind of company it is so you know if its revenues are more likely to grow or shrink over time. For example, a software company's revenue is expected to increase yearly due to new products and services that its customers will want to buy. At the same time, a car manufacturer might not be able to sell as many cars when the economy slows down, so it would have less net income during those times. Second, pay attention to its debt-to-equity ratio because this number will tell you how much risk it has. If a company such as Zentalis PharmaceuticalsL is not taking on any additional risks, its debt-to-equity should be less than one. As a general rule of thumb, if the market value or book value (which can be found in the footnotes) of assets exceeds the company's liabilities, then it is probably in good shape. Finally, use other financial statements to determine if a stock price will go up or down because investors are always looking for growth opportunities when they buy new stocks. For example, if you see that the net revenue of Zentalis has grown by more than 25% over the last five years, then there is a good chance that it will continue growing by at least 20% or more each year. On the other hand, if you see that net revenue has only increased by about 15%, which is barely above inflation levels, then chances are it will not grow much faster than this over time, and investors may shy away from buying it.
In summary, you can determine if Zentalis PharmaceuticalsL's financials are consistent with your investment objective using the following steps:
  • Review Zentalis PharmaceuticalsL's balance sheet accounts, such as liabilities and equity, to understand its overall financial position.
  • Analyze the income statement and examine the company's revenue, expenses, and profits over time to determine its financial performance.
  • Study the cash flow inflows and outflows to understand Zentalis PharmaceuticalsL's liquidity and solvency.
  • Look at the growth rates in revenue, earnings, and cash flow over time to determine its potential for future growth.
  • Compare Zentalis PharmaceuticalsL's financials to those of its peers to see how it stacks up and identify any potential red flags.
  • Use valuation ratios to evaluate the company's financials using commonly used ratios such as the price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and enterprise value-to-earnings before interest, taxes, depreciation, and amortization (EV/EBITDA) ratio to determine if Zentalis PharmaceuticalsL's stock is overvalued or undervalued.
Remember, these are just guidelines and should not be the only basis for investment decisions. It is always important to conduct additional research and seek professional advice.

Zentalis PharmaceuticalsL March 26, 2023 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Zentalis PharmaceuticalsL help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Zentalis PharmaceuticalsLlc. We use our internally-developed statistical techniques to arrive at the intrinsic value of Zentalis PharmaceuticalsLlc based on widely used predictive technical indicators. In general, we focus on analyzing Zentalis Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Zentalis PharmaceuticalsL's daily price indicators and compare them against related drivers.
Check out Your Current Watchlist. For more information on how to buy Zentalis Stock please use our How to buy in Zentalis Stock guide. You can also try Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.

Complementary Tools for analysis

When running Zentalis PharmaceuticalsL price analysis, check to measure Zentalis PharmaceuticalsL's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Zentalis PharmaceuticalsL is operating at the current time. Most of Zentalis PharmaceuticalsL's value examination focuses on studying past and present price action to predict the probability of Zentalis PharmaceuticalsL's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Zentalis PharmaceuticalsL's price. Additionally, you may evaluate how the addition of Zentalis PharmaceuticalsL to your portfolios can decrease your overall portfolio volatility.
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Bond Directory
Find actively traded corporate debentures issued by US companies
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Is Zentalis PharmaceuticalsL's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zentalis PharmaceuticalsL. If investors know Zentalis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zentalis PharmaceuticalsL listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
Return On Assets
Return On Equity
The market value of Zentalis PharmaceuticalsL is measured differently than its book value, which is the value of Zentalis that is recorded on the company's balance sheet. Investors also form their own opinion of Zentalis PharmaceuticalsL's value that differs from its market value or its book value, called intrinsic value, which is Zentalis PharmaceuticalsL's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zentalis PharmaceuticalsL's market value can be influenced by many factors that don't directly affect Zentalis PharmaceuticalsL's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Zentalis PharmaceuticalsL's value and its price as these two are different measures arrived at by different means. Investors typically determine Zentalis PharmaceuticalsL value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zentalis PharmaceuticalsL's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.